Ondine Biomedical Inc.
OBIMF
$0.11
-$0.02-15.39%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 24.64% | 26.09% | 28.11% | 57.59% | 67.37% |
| Total Depreciation and Amortization | 0.00% | 7.55% | 14.81% | 20.69% | 29.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -3.88% | -- |
| Total Other Non-Cash Items | -58.34% | -58.57% | -59.32% | -96.84% | -97.95% |
| Change in Net Operating Assets | 1,118.38% | 4,609.52% | -590.95% | 65.98% | 93.55% |
| Cash from Operations | 22.99% | 20.84% | 19.54% | 20.38% | 19.88% |
| Capital Expenditure | 94.03% | 64.88% | 46.01% | 37.55% | 27.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 94.03% | 64.88% | 46.01% | 37.55% | 27.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -35.38% | -50.26% | -69.44% | 36.33% | 65.02% |
| Issuance of Common Stock | -- | -- | -- | -86.98% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -8,378.26% | -2,943.48% | 41.96% | 100.00% |
| Cash from Financing | 2,927.95% | 2,233.91% | 1,419.07% | -91.76% | -100.77% |
| Foreign Exchange rate Adjustments | -76.29% | -101.58% | -126.65% | 9.17% | 358.72% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.54% | 60.21% | 41.22% | -691.93% | -175.21% |
